# Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lenvatinib-versus-sorafenib-for-first-line-treatment-of-unresectable/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Arndt Vogel,Shukui Qin,Masatoshi Kudo,Yun Su,Stacie Hudgens,Tatsuya Yamashita,Jung‐Hwan Yoon,Lætitia Fartoux,Krzysztof Simon,Carlos López,Max W. Sung,Kalgi Mody,Tatsuroh Ohtsuka,Toshiyuki Tamai,L. Michelle Bennett,Genevieve Meier,Valery Breder |
| Citations | 153 |
| DOI | 10.1016/s2468-1253(21)00110-2 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3165018140 |
| PMID | 34087115 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Stacie Hudgens](https://scholariq.org/researchers/stacie-hudgens/)

## Paper journal

- [˜The œLancet. Gastroenterology & hepatology](https://scholariq.org/journals/the-lancet-gastroenterology-and-hepatology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.